scholarly journals Intra-ovarian injection of platelet-rich plasma into ovarian tissue promoted rejuvenation in the rat model of premature ovarian insufficiency and restored ovulation rate via angiogenesis modulation

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Shahin Ahmadian ◽  
Sepideh Sheshpari ◽  
Mohammad Pazhang ◽  
Alberto Miranda Bedate ◽  
Rahim Beheshti ◽  
...  
Keyword(s):  
Rat Model ◽  
Platelet Rich Plasma ◽  
Ovarian Tissue ◽  
Ovulation Rate ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency

scholarly journals Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women

2020 ◽  
Vol 9 (6) ◽  
pp. 1809 ◽  
Author(s):  
Konstantinos Sfakianoudis ◽  
Mara Simopoulou ◽  
Sokratis Grigoriadis ◽  
Agni Pantou ◽  
Petroula Tsioulou ◽  
...  
Keyword(s):  
Pilot Study ◽  
Outcome Measures ◽  
Primary Outcome ◽  
Platelet Rich Plasma ◽  
Premature Ovarian Insufficiency ◽  
Cycle Performance ◽  
Routine Practice ◽  
Ovarian Insufficiency ◽  
Pilot Studies ◽  
Pilot Data

Intraovarian platelet-rich plasma (PRP) infusion was recently introduced in the context of addressing ovarian insufficiency. Reporting on its effectiveness prior to adopting in clinical routine practice is imperative. This study aims to provide pilot data regarding PRP application for ovarian rejuvenation. Four pilot studies were conducted on poor ovarian response (POR), premature ovarian insufficiency (POI), perimenopause, and menopause, respectively. Each pilot study reports on thirty patients, 120 participants were recruited in total. All participants provided written informed consent prior to treatment. Primary outcome measures for the POR pilot study were levels of anti-müllerian hormone (AMH), antral follicle count (AFC) and oocyte yield. For the POI, perimenopausal and menopausal pilot studies primary outcome measures were restoration of menstrual cycle, and Follicle Stimulating Hormone (FSH) levels. A significant improvement on the hormonal profile and the ovarian reserve status was noted, along with improved intracytoplasmic sperm injection (ICSI) cycle performance concerning POR participants. Menstruation recovery was observed in 18 out of 30 POI patients, along with a statistically significant improvement on levels of AMH, FSH, and AFC. Similarly, 13 out of 30 menopausal women positively responded to PRP treatment. Finally, menstruation regularity, improved hormonal levels and AFC were reported for 24 out of 30 perimenopausal women. To conclude, PRP infusion appears to convey promising results in addressing ovarian insufficiency.

scholarly journals Fertility Preservation: Current and Future Perspectives for Oncologic Patients at Risk for Iatrogenic Premature Ovarian Insufficiency

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Sara Pinelli ◽  
Stefano Basile
Keyword(s):  
Fertility Preservation ◽  
Ovarian Tissue ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Tissue Cryopreservation ◽  
Adult Women ◽  
Childbearing Age ◽  
Ovarian Insufficiency ◽  
Require Time ◽  
Early Diagnosis Of Cancer ◽  
Oncologic Patients

Progress in recent years in the efficacy of oncologic treatment and early diagnosis of cancer has determined an increase in life expectance in cancer patients. About 10% of all cancer cases affect women younger than 45 years; therefore nowadays approximately 5-6% of the population in childbearing age consists in cancer survivors. A crucial issue is the high risk of premature ovarian insufficiency due to possible gonadotoxic effects of oncologic treatments. Considering combined chemotherapy, radiation therapy, and bone marrow transplantation, this risk can reach 92-100%, depending on the age and ovarian reserve of the patient, as well as the schedule and type of therapy. International guidelines recommend addressing all the patients diagnosed with a neoplasia treatable with potentially gonadotoxic therapies to fertility preservation. Moreover, fertility preservation also seems to reserve fascinating implications for women who want to delay childbearing for social reasons or women affected with endometriosis, who could receive unexpected opportunities. At present, the most widespread techniques to preserve fertility in adult women are embryo or oocyte cryopreservation, depending on the presence of a partner or according to legislative issues, but these procedures require time for ovarian stimulation. In prepubertal patients or when there is no possibility of delaying chemotherapy, ovarian tissue cryopreservation and subsequent transplantation represent the main strategy.

scholarly journals Association between Serum Vitamin A Levels and Premature Ovarian Insufficiency Risk

2021 ◽  
Author(s):  
Yang Song ◽  
Peiqiong Chen ◽  
Wenxian Xu ◽  
Yizhou Huang ◽  
Yingxian Jia ◽  
...  
Keyword(s):  
Vitamin A ◽  
Vitamin A Deficiency ◽  
Lipid Level ◽  
Ovarian Tissue ◽  
Serum Vitamin ◽  
Premature Ovarian Insufficiency ◽  
Control Group ◽  
Binary Logistic Regression Analysis ◽  
Ovarian Insufficiency ◽  
Negatively Associated

Abstract Purpose: The aim of the study was to explore the association between serum vitamin A levels and premature ovarian insufficiency (POI). Methods: In this cross-sectional survey, women with POI (n = 47) and normo-ovulatory controls (n = 67) were enrolled from December 2016 to May 2018 in Zhejiang, China. The serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), anti-Müllerian hormone (AMH), vitamin A, and total cholesterol (TC) were measured for each participant. The association of vitamin A levels with POI risk was assessed using binary logistic regression analysis. Results: Serum vitamin A levels seems slightly higher in the POI group than in the control group (728.00 ± 176.00 vs 503.93 ± 145.64 µg/L, p = 0.133). But after adjust with serum lipid level, serum vitamin A/TC ratio was significantly lower in the POI group than in the control group (143.14 ± 35.86 vs 157.56 ± 35.21 µg/mmol, p = 0.035). Further, serum vitamin A/TC ratio was significantly and negatively associated with POI risk [unadjusted odds ratio (OR) = 0.988, 95% confidence interval (CI): 0.977–0.999, p = 0.039]. The same trend was found after adjusting for confounding factors (age, BMI, annual household income, and education) (OR = 0.986, 95% CI: 0.972–0.999, p = 0.040). Conclusion: Serum vitamin A/TC ratio was negatively associated with POI risk, indicating that vitamin A deficiency may be a risk factor for POI development. Serum vitamin A/TC ratio may serve as a predictive factor for POI incidence. Thus, vitamin A may serve a protective role in ovarian tissue.

scholarly journals iPSC-Derived Ovarian Tissue Restores Ovarian Function in Subfertile Mice and After Gonadotoxic Chemotherapy

2019 ◽  
Author(s):  
K.M. Elias ◽  
N.W. Ng ◽  
K.U. Dam ◽  
A. Milne ◽  
E.R. Disler ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Nude Mice ◽  
Ovarian Tissue ◽  
Stem Cell Differentiation ◽  
Reproductive Hormones ◽  
Reproductive Age ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency ◽  
Hormone Synthesis

AbstractMany reproductive age women with cancer who receive chemotherapy are exposed to gonadotoxic agents and risk diminished ovarian reserve, sterility, and premature menopause. Previously, we reported the derivation of steroidogenic ovarian cells from induced pluripotent and embryonic stem cells. Derived cells not only produced reproductive hormones, but also displayed markers of ovarian tissue and primordial gametes. Here, we describe that human follicular fluid (HFF), when added to our stem cell differentiation system, enhances the steroidogenic potential of differentiating stem cells and increases the subpopulation of cells that express the ovarian and germ cell markers GJA1 and ZP1, respectively. More importantly, using an in vivo model of chemotherapy-induced premature ovarian insufficiency in subfertile nude mice, we demonstrate that orthotopic implantation of these derived cells restores ovarian hormone synthesis and produces functional stem cell-derived oocytes. Additionally, these cells also ameliorate subfertility in nude mice, as demonstrated by the delivery of multiple litters of healthy pups from stem cell-derived oocytes. Collectively, these data support the hypothesis that stem cell-derived steroidogenic ovarian tissue could be used to promote neo-gametogenesis and treat the endocrinologic and reproductive sequelae of premature ovarian insufficiency.One Sentence SummaryWe show that orthotopic injection of sorted, differentiated iPSCs in ovaries of subfertile mice restores reproductive hormone synthesis and fertility.

Sign in / Sign up

Export Citation Format

Share Document